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Abstract
B-Chronic Lymphocytic Leukemia (CLL) is an incurable disease predominantly characterized by
apoptosis resistance. We have previously described a VEGF signaling pathway that generates
apoptosis resistance in CLL B cells. We found induction of significantly more apoptosis in CLL B
cells by co-culture with an anti-VEGF antibody. To increase the efficacy of these agents in CLL
therapy we have focused on the use of gold nanoparticles (GNP). Gold nanoparticles were chosen
based on their biocompatibility, very high surface area, ease of characterization and surface
functionalization. We attached VEGF antibody (AbVF) to the gold nanoparticles and determined
their ability to kill CLL B cells. Gold nanoparticles and their nanoconjugates were characterized
using UV-Visible spectroscopy (UV-Vis), transmission electron microscopy (TEM),
thermogravimetric analysis (TGA) and X-ray photoelectron spectroscopy (XPS). All the patient
samples studied (N = 7) responded to the gold-AbVF treatment with a dose dependent apoptosis
of CLL B cells. The induction of apoptosis with gold-AbVF was significantly higher than the CLL
cells exposed to only AbVF or GNP. The gold-AbVF treated cells showed significant down
regulation of anti-apoptotic proteins and exhibited PARP cleavage. Gold-AbVF treated and GNP
treated cells showed internalization of the nanoparticles in early and late endosomes and in
multivesicular bodies. Non-coated gold nanoparticles alone were able to induce some levels of
apoptosis in CLL B cells. This paper opens up new opportunities in the treatment of CLL-B using
gold nanoparticles and integrates nanoscience with therapy in CLL. In future, potential
opportunities exist to harness the optoelectronic properties of gold nanoparticles in the treatment
of CLL.
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Background
There is increasing evidence that angiogenesis plays a crit-
ical role in the pathogenesis of human malignancies [1,2].
Angiogenesis is an event that relies on the formation of
vessels from preexisting vasculature that occurs in health
and disease. Initially it was found that without new capil-
lary formation there could not be significant tumor
growth or metastasis to other organ sites. While the origi-
nal evidence for this was based on the finding of tissue
neovascularization, there have been significant advances
delineating the presence of autocrine and/or paracrine
pathways in both solid tumors and human leukemias
[3,4]. Hematological diseases with aberrant vasculariza-
tion include; multiple myeloma, acute myeloid leukemia
and more recently B-chronic lymphocytic leukemia
(CLL). These findings have led to the exciting possibility
that strategies that undermine the angiogenic pathways
could be used as non-overlapping methods of treatment
for these diseases [5].
Initially the secretion of VEGF from malignant tumors was
believed to be of primary importance in the development
of neovascularization of the tumor involved tissue sites.
This important biologic event was associated with more
aggressive disease status. However more recently the para-
crine role of VEGF has been modified to include autocrine
pathway(s) that increase survival of malignant cells in
both mouse and human tumor types [6]. Interruption/
blockade of the VEGF pathway in those tumor cells has
been shown to lead to cell death. To a great extent the level
of interruption/blockade has been either to bind VEGF or
to inhibit VEGFR-1 or VEGFR-2 [7,8]. Importantly, our-
selves and others have found that CLL B cells secrete VEGF
and express the VEGF receptors; VEGFR-1, VEGFR-2 and
Neuropilin-1 (NRP-1) [9]. The VEGF based pathway
appears to be important in the apoptosis resistance of CLL
B cells. Thus we have found that culturing CLL B cells with
receptor tyrosine kinase inhibitors or anti-VEGF antibod-
ies (Avastin; bevacizumab) leads to increased levels of
apoptosis. However, significantly high amount of the
antibody was required to have a moderate effect in the
apoptosis. In order to enhance the efficacy of agents such
as anti-VEGF antibodies we have conducted initial studies
utilizing delivery of these antibodies via conjugated gold
nanoparticles. The primary rationale for selecting gold
nanoparticles is their biocompatibility, very high surface
area (large amount of drugs can be loaded), ease of char-
acterization and surface modification (i.e. organic mole-
cules such as drugs, peptides, antibodies, etc. can be easily
attached to gold nanoparticles)[10]. This report details
our initial work with anti-VEGF (AbVF) conjugated to
gold nanoparticles in comparison to naked anti-VEGF
antibody or gold nanoparticles alone in the modulation
of the apoptotic status of CLL B cells.
Results and discussion
Synthesis of gold nanoparticles and conjugation with anti-
VEGF antibody
Gold nanoparticles were synthesized according to stand-
ard wet chemical methods using sodium borohydride as a
reducing agent [11-13]. Characteristic surface plasmon
resonance (SPR) band of gold nanoparticles was observed
in the UV-Visible spectrum, confirming the presence of
spherical gold nanoparticles (Figure 1a). TEM micro-
graphs showed spherical gold nanoparticles of approxi-
mately 4 nm were formed by this method (Figure 1b). Size
distribution analysis clearly showed that nearly 90% of
the particles reside within 4 nm size range (Figure 1c).
Gold nanoparticles obtained by this method were centri-
fuged at 13,000 rpm for 45 min at 10°C. The loose pellet
at the bottom was collected and analyzed for gold content
using inductively coupled plasma (ICP) analysis. The con-
centration of gold was found to be 200 µg/ml. The gold
nanoparticles obtained after ultracentrifugation was fil-
tered through 0.22 µM filter paper and UV-irradiated for
15 minutes before their use in the apoptosis assay as con-
trol for Au-AbVF.
The decision to establish feasibility of anti-VEGF antibody
conjugation to gold nanoparticles was based on our ear-
lier observations that anti-VEGF antibodies alone could
induce apoptosis of CLL B cells [14]. However we wished
to develop maneuvers that would enhance the ability of
the anti-VEGF antibody to kill CLL B cells. Attachment of
VEGF antibody (AbVF) to gold nanoparticles was done
according to published literature and monitored using
UV-Visible spectroscopy (Shimadzu, UV2401 PC)
because the SPR is very sensitive to surface modification of
the gold nanoparticles. An increase in absorbance of gold
nanoparticles with a concomitant red shift in the λmax was
also observed as reported earlier [13]. The increase in
absorbance and red shift in the λmax indicates the pertur-
bation of the electrical double layer present around the
gold nanoparticles on the addition of AbVF and confirms
its attachment on the gold nanoparticles [13]. Finally, the
concentration of AbVF on gold nanoconjugates and its
nature of bonding with gold nanoparticles were deter-
mined using thermogravimetric analysis (TGA) and X-ray
photoelectron spectroscopy (XPS). For TGA, 150 ml gold
nanoparticles were incubated with 600 µg of AbVF. After
1 h, the nanoconjugates were centrifuged at 25000 rpm
for 1 h, freeze-dried overnight and analyzed using TGA.
Figure 2a and 2b describe the TGA profile of Au-AbVF
nanoconjugates. Figure 2a clearly shows a total weight
loss of 12% spanning over three distinct steps of weight
losses at 200°C, 250°C and 375°C. The graph of deriva-
tive weight loss over temperature (Fig. 2b) shows three
distinct maxima of weight losses at nearly 240°C, 320°C
and 400°C. A weight loss of 13.3% should be observed
according to theoretical calculation (where 1 ml gold nan-Journal of Nanobiotechnology 2007, 5:4 http://www.jnanobiotechnology.com/content/5/1/4
Page 3 of 13
(page number not for citation purposes)
UV-Visible spectroscopy and transmission electron micrograph of gold nanoparticles Figure 1
UV-Visible spectroscopy and transmission electron micrograph of gold nanoparticles. a) UV-visible spectrum of a gold nano-
particles solution and b) Transmission electron microscopy picture of gold nanoparticles. TEM was done after drop coating the 
gold nanoparticles on carbon coated copper grid, c) histogram showing the size distribution of gold nanoparticles.Journal of Nanobiotechnology 2007, 5:4 http://www.jnanobiotechnology.com/content/5/1/4
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oparticles solution containing 26 µg of gold was incu-
bated with 4 µg of AbVF). Therefore, a total weight loss of
12% accounts for 90% of the AbVF used initially for
attachment was actually bound to gold nanoparticles.
Three different weight losses at three different tempera-
tures indicate that there are, at least, three different modes
of bonding between AbVF and gold nanoparticles. Gold is
known to bind strongly with organic molecules contain-
ing thiols and amines groups [18]. The formation of self-
assembled monolayers of organothiols on gold surfaces
has been attributed to its ability to bind thiolates cova-
lently [16,17]. Since the discovery of immunogold labe-
ling in 1971 by Faulk and Taylor, a great deal of
information is known about the nature of bonding
between gold nanoparticles and antibodies [18]. It is now
well recognized that there are, at least, three separate but
dependent phenomenon that might explain the bonding
of AbVF to gold nanoparticles; i) electrostatic attraction of
negatively charged gold nanoparticles with positively
charged protein molecules, ii) covalent bonding between
the thiols/amine groups present within the amino acids in
the antibody and the gold nanoparticles, and iii) hydro-
phobic interaction between proteins and gold nanoparti-
cles [19]. Our data suggests that after being
electrostatically attracted to gold nanoparticles, AbVF
(having a lysine and cysteine residues) binds covalently to
the gold nanoparticles through the thiol/amine groups.
The small amount of weight losses at relatively lower tem-
perature is suggestive of a weaker interaction between
gold and the antibody and we speculate it to be hydro-
phobic in nature. A second weight loss at higher tempera-
ture (320°C) indicates another distinctly different
bonding mode that needed much higher energy to des-
orb/decompose the antibody from the nano-gold sur-
faces. The maximum weight loss at this temperature is
most likely due to the presence of gold-sulfhydryl/gold-
amine bond where the antibody is held to the nano gold
surface through covalent interaction between the gold
nanoparticles and cysteine/lysine residues present in the
antibody [20]. A third weight loss at the even higher tem-
perature (400°C) was suggestive of the presence of a third
complex mode of attachment of the antibody to gold nan-
oparticles that requires higher energy to desorb/decom-
pose from the nanogold surfaces.
The nature of bonding between gold and AbVF was fur-
ther supported by X-ray photoelectron spectroscopy
(XPS). A single gold (Au 4f7/2) peak at 83.2 eV with a spin
orbit coupling of 3.7 eV was observed in the drop-coated
conjugates. These data clearly demonstrate that all of the
Au+3 ions used in the process were reduced to Au0 by
sodium borohydride (Fig. 2c) [11,21]. Two weak sulfur
peaks were also observed. The presence of two sulfur
peaks at 162.7 and 167.1 eV represents two chemically
distinct sulfur species (data not shown). We observed sim-
ilar sulphur peaks from gold conjugates containing
VEGF165, a growth factor [11]. This is not unexpected
because both the VEGF165 and AbVF are proteins and it is
reasonable to assume that they use similar chemical enti-
ties such as cysteine or lysine residues to bind to gold nan-
oparticles. The peak at 162.7 eV can be assigned to gold-
thiolate bond and peaks at higher binding energy (BE) to
sulfones, an oxidized sulfur species. The origin of this sul-
fone peak may arise due to aerial oxidation of the sulfur
during sample preparation [11]. Unbound thiol peaks
normally appear at 164 eV [21]. The nitrogen 1s peak at
399.6 eV (Fig 2d) is likely due to unionized, non-proto-
nated nitrogen [22]. This is in agreement with earlier stud-
ies reported on the adsorption of proteins/amino acids or
amines on gold surfaces [22,23]. Therefore, we speculate
that AbVF may bind to gold nanoparticles through -NH2
functionalities via pseudo-covalent interaction. Hence, we
infer from the XPS and TGA studies that AbVF binds to
gold nanoparticles through sulfur and/or nitrogen present
in the cysteine/lysine residues in the antibody. Following
the establishment of a protocol that we could reliably gen-
erate and characterize gold nanoparticles conjugated to
AbVF we then explored the ability of this conjugate to
alter leukemic B cell apoptosis. For the apoptosis experi-
ments, 150 ml gold nanoparticles were incubated with
600 µg of AbVF and purified through ultracentrifugation
as described above and then used for the study after UV-
Irradiating the particles for 20–30 minutes. Exactly the
same amount of gold nanoparticles (Au) and AbVF
present in the respective doses of Au-AbVF were separately
used as controls. It is important to mention here that in
the case of AbVF and Au-AbVF treated groups, the doses
are always referred to based on the amount of AbVF
present in the nanoconjugates, e. g, 25 µg Au-AbVF corre-
sponds to 25 µg AbVF present in the nanoconjugates.
However, in the case of gold treated groups the doses of 1,
5 and 25 µg correspond to the exactly same amount of
gold present in 1, 5, and 25 µg of Au-AbVF respectively.
Impact of gold nanoparticles (Au), and gold nanoparticles 
conjugated with AbVF (Au-AbVF) and AbVF on CLL B cell 
apoptosis
It is also important to note here that there is hardly any
preclinical model available for CLL-B studies. Therefore,
studies with primary CLL-B cells (cells isolated directly
from patient blood) are considered as a preclinical study.
Figure 3 describes the dose dependent behavior of AbVF,
Au and Au-AbVF in inducing apoptosis of CLL B cells iso-
lated from 7 different patients. CLL B cells were incubated
with AbVF, Au and Au-AbVF separately for 72 hours fol-
lowed by apoptosis measurement using Annexin/PI anal-
ysis. Figure 3a describes the effect of different doses of
AbVF in inducing apoptosis.Journal of Nanobiotechnology 2007, 5:4 http://www.jnanobiotechnology.com/content/5/1/4
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Among the 7 samples, 3 samples (P3, P5 and P7) showed
moderate apoptosis levels (~40%) in a dose dependent
manner; maximum apoptosis was observed at highest
dose (25 µg). For the remaining 4 samples, 2 showed no
effect (Sample P4 and P6) and 2 showed only a partial
apoptosis above baseline (~10%). Figure 3b describes the
effect of gold nanoparticles alone in the induction of
apoptosis in CLL-B cells. The amount of gold nanoparti-
cles used is exactly the same as in the respective doses of
Au-AbVF. From this figure it is clear that 3 (P1, P2, P3)
samples responded to the exposure to gold nanoparticles
alone with increases in apoptosis (~50–60% apoptosis
was observed) in a dose dependent manner. Among the
remaining 4 samples, 2 did not respond at all (P6, P7) and
lesser levels of apoptosis induction were observed for the
remaining 2 samples (P4, P5). Figure 3c describes the
effect of Au-AbVF in the induction of apoptosis in CLL-B
cells isolated from patients. From figure 3c it is evident
that all the 7 samples responded more effectively to the
gold-AbVF treatments in terms of apoptosis induction.
Significant increases in apoptosis (~80%) in a dose
dependent manner were observed in 4 out of the 7 CLL
Thermogravimetric analysis (TGA) of Au-AbVF conjugates Figure 2
Thermogravimetric analysis (TGA) of Au-AbVF conjugates. For TGA, 150 ml gold nanoparticles were incubated with 600 µg of 
AbVF. After 1 h, the nanoconjugates were centrifuged at 25000 rpm for 1 h, freeze-dried overnight and analyzed using TGA; 
2a) describes weight loss over temperature and 2b) derivative weight loss over temperature for the nanoconjugates. TGA anal-
ysis was done on purified and lyophilized nanoconjugates, 2c) X-ray photoelectron spectra of Au-AbVF conjugates. Core level 
BE of Au and 2d) core level BE of N.Journal of Nanobiotechnology 2007, 5:4 http://www.jnanobiotechnology.com/content/5/1/4
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Dose dependent effect of AbVF, Au and Au-AbVF in the induction of apoptosis in CLL-B cells Figure 3
Dose dependent effect of AbVF, Au and Au-AbVF in the induction of apoptosis in CLL-B cells. Cells were treated with 1, 5 and 
25 ug of AbVF/Au/Au-AbVF for 72 h followed by measurement of apoptosis using annexin PI. The % apoptosis was calculated 
after normalizing the apoptosis in the control cells (no treatment group) to zero; 3a) effect of AbVF to induce apoptosis in 
CLL-B cells; 3b) effect of Au nanoparticles only to induce apoptosis in CLL-B and figure 3c) effect of Au-AbVF to induce apop-
tosis in CLL B cells. In the case of AbVF treated group, the amount of AbVF used is exactly the same in the corresponding 
doses of Au-AbVF. Similarly, in case of gold treated group, the amount of gold nanoparticles used is exactly the same as in the 
corresponding doses of Au-AbVF.Journal of Nanobiotechnology 2007, 5:4 http://www.jnanobiotechnology.com/content/5/1/4
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samples and a significant enhancement in the apoptosis
was observed in all the samples compared to Au and AbVF
controls. The apoptosis induction observed in the case of
control gold nanoparticles (Au treatment group) on CLL
B cells is not surprising as we have shown previously that
the gold nanoparticles posses unique antiangiogenic
properties [11-13]. Recently, it has been reported that
gold nanoparticles inhibit the function of heparin bind-
ing growth factors such as VEGF165, BFGF and posses
anti-angiogenic properties. Therefore, gold nanoparticles
alone without any modification can inhibit the function
of some of the growth factors secreted by the CLL B cells
and hence the induction of apoptosis [11,12].
Figure 4 describes the time course of the effect of AbVF, Au
and Au-AbVF in the induction of apoptosis to CLL-B cells.
CLL-B cells were treated with 5 µg/ml of AbVF either
bound or non-bound to gold as well as gold controls sep-
arately for 24 h, 48 h and 72 h respectively (the amount
of gold in the control Au-treated good is exactly the same
here as in 5 µg of Au-AbVF). Figure 4a shows the effect of
non-conjugated AbVF to induce apoptosis in CLL-B cells
treated with 5 µg/ml of AbVF. After the respective time
points, cells were analyzed for apoptosis using annexin/PI
method. Figure 4a shows the effect of non-conjugated
AbVF over time and a clear level of apoptosis induction
over baseline was observed in 3 samples out of 7 (P5, P6,
P7). However, no clear time dependent apoptosis was
observed with the 5 µg/ml dose. Figure 4b describes the
effect of Au nanoparticles on the time dependent induc-
tion of apoptosis of CLL-B cells (n = 7). Time dependent
apoptosis was observed for P1 and P3 where maximum
apoptosis was observed at 72 h, however P2, P4 and P7
did not respond with apoptosis induction to the nano-
gold particles. For P5 and P6, time dependent apoptosis
was observed for first 48 h, however, no apoptosis was
observed at 72 h. We believe these residual B cells were
resistant to the nonconjugated Au nanoparticles. The
degree of apoptosis observed from the treatment with
gold nanoparticles alone is not unexpected due to the
anti-angiogenic properties of gold nanoparticles, as
described above. Figure 4c describes the effect of Au-AbVF
in the induction of apoptosis in CLL B cells. With this con-
jugate time dependent apoptosis was observed with max-
imum apoptosis observed at 72 h for all CLL B cells.
Importantly in the case of Au-AbVF treated samples for
both experiments depicted in figure 3 and 4, all the CLL B
cell samples showed significantly higher induction in
apoptosis (2–5 fold) compared to either the AbVF treat-
ment group or gold treatment groups (Fig 4d). It is also
important to mention here that control experiments with
same doses of nanoconjugates used in CLL-B cell studies
using peripheral blood mononuclear cells (PBMCs) iso-
lated from normal healthy individual did not induce sig-
nificant apoptosis. Only a less than 10% apoptosis was
observed with the highest does of Au alone or AbVF or Au-
AbVF whereas the lower doses did not induce any signifi-
cant apoptosis.
Various autocrine pathways in CLL B cells provide impor-
tant survival advantages for these cells. We have already
established that a VEGF autocrine pathway exists in CLL B
cells [7]. The evidence for this includes our finding that
recombinant VEGF165 can rescue CLL B cells from both
spontaneous and drug-induced apoptosis. The addition of
VEGF to CLL B cells also resulted in significant increases
in the antiapoptotic proteins Mcl-1 and XIAP. In addition
we found that the two VEGF receptors (VEGF-R1 and
VEGF-R2) on CLL B cells are spontaneously phosphor-
ylated. The combination of VEGF-induced increases in
anti-apoptotic proteins combined with the finding of
phosphorylated VEGF receptors strongly suggested that a
VEGF-based pathway is linked to CLL Bcell survival. We
consistently found that the anti-apoptotic protein Mcl-1
was increased when CLL B cells were exposed to exoge-
nous VEGF165 [3]. To find out the mechanism of more
effective induction in apoptosis in CLL-B cells by Au-AbVF
conjugates, we looked at the levels of Mcl-1, PARP, BcL-2
and caspase3 in CLL-B cells treated with different doses of
Au, AbVF and Au-AbVF. Figure 5, shows that CLL B cells
have clearly detectable PARP cleavage, decrease in cas-
pase-3, Mcl-1 and Bcl-2 for Au-AbVF exposed cells but not
for Au control or AbVF alone. Thus we believe that the
AbVF conjugated to gold nanoparticles are inducing apop-
tosis in the CLL B cells similar to what we have found with
VEGF pathway blockade using bevacizumab alone, but
Au-AbVF is more effective than naked antibody 2C3 (i.e.
2–5 fold increase in induction of apoptosis). Previously,
we have shown our ability to bind anti-angiogenic mole-
cules and anti-cancer drugs on a single gold core in a
"spoke in a wheel" fashion [13]. This study details our
ability to enhance the efficacy of anti-VEGF antibody,
2C3, when conjugated to gold nanoparticles with result-
ant significant enhancement in apoptosis of primary CLL
B cells when compared to an anti-VEGF antibody or gold
nanoparticles alone. The reason for such an enhanced
activity of Au-AbVF towards apoptosis induction is cur-
rently unknown and a subject of future investigation, but
we believe that enhancing efficacy of the antibodies and
lowering of the doses when delivered as gold nanoconju-
gates will have tremendous implications in the treatment
of CLL.
Fate of gold nanoparticles and its conjugates after 
treatment
It is also important to know the fate of the nanoparticles
after the treatment. Do the cells internalize the particles or
do the particles remain bound to the cell membrane? To
address these issues transmission electron microscopy of
the cells treated with gold nanoparticles alone and withJournal of Nanobiotechnology 2007, 5:4 http://www.jnanobiotechnology.com/content/5/1/4
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Au-AbVF for 1 h is performed [24]. The 1 h treatment
duration was chosen based on previously reported litera-
ture on the internalization of gold nanoparticles as longer
time points did not increase gold uptake nor does it alter
the pattern of internalization. Figure 6 exhibits the inter-
nalization of Au-AbVF by primary CLL-B cells after 1 h
treatment. All the features of early as well as late internal-
ization were clearly visible. Nanoconjugates were found at
the cell periphery (within uncoated tubules and vacuoles,
Figure 6a, b). Gold nanoparticles were also detected
within larger endocytic compartments of diverse mor-
phology. These include peripherally both early and late
endosomes and lysozomes (6c, 6d). Similar pattern of
internalization was observed when the cells were treated
with gold nanoparticles alone (Figure 6e–6h). However,
in this case, the number of gold nanoparticles taken up by
the cells was found to be much lower than the previous
case and lots of aggregated gold nanoparticles were seen.
Since, the focus of this paper is not to find out the endo-
cytic pathway of gold nanoparticles/gold nanoconjugates
by primary CLL-cells, so further detailed studies to find
out the mechanisms of internalization was not per-
Effect of time on the induction of apoptosis of CLL-B cells by AbVF, Au and Au-AbVF Figure 4
Effect of time on the induction of apoptosis of CLL-B cells by AbVF, Au and Au-AbVF. Cells were treated with 5 ug/ml of 
AbVF/Au/Au-AbVF for 72 h. Apoptosis measurement was then done using annexin/PI and apoptosis was calculated as 
described above; 4a) effect of AbVF alone; 4b) effect of Au alone; 4c) effect of Au-AbVF alone and 3d) comparison of the effi-
cacy of AbVF, gold and gold-AbVF, 4d) comparison of effect of AbVF, Au and Au-AbVF on the apoptosis of CLL-B cells. To 
compare the activity of AbVF either conjugated or free the amount of AbVF used as control is exactly the same amount of 
AbVF present in the nanoconjugate. Similarly, to compare the activity of Au and Au-AbVF the amount of Au used as control is 
exactly the same amount of Au present in the nanoconjugate. The quantitations of Au in the nanoparticles solution and in the 
purified nanoconjugates were determined using inductively couple plasma analysis (ICP).
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formed. But, we speculate that the particles may be taken
up by classical pinocytic mechanism of engulfing particles
of very smaller size.
While we may be concerned about the possible toxicities
of gold nanoparticles in human therapies, colloidal gold
actually has a long history of use in humans [25,26]. The
therapeutic use of gold can be traced back to the Chinese
in 2500 BC [10]. They were the first to prepare and use red
colloidal gold as the "drug of longevity." Red colloidal
gold is still in use today in India in the form of Ayurvedic
medicine for rejuvenation and revitalization during old
age under the name of Swarna Bhasma ("Swarna" mean-
ing gold, "Bhasma" meaning ash) [27,28]. Further evi-
dence of gold nanoparticles as potential non-toxic agents
comes from our murine preclinical model in which we
show that intraperitoneal administration of gold nano-
particles to C3H mice does not cause any acute biochem-
ical and/or hematological toxicities [13]. In vitro, the non-
toxic behavior of gold nanoparticles has also been
addressed by other groups including ours [29-31].
Another recent report has shown in a preclinical mouse
model, that doses of gold nanoparticles as high as 2.7 g/
kg body weights did not cause any significant toxicity in
mice up to 1 year of study [32]. Furthermore, light absorb-
ing properties of gold nanoparticles has been exploited to
inflict localized damage to cells at sublethal levels to tran-
siently modify cellular functions [33]. Gold-silica
nanoshell has been used in nanoshellassisted photo-ther-
mal therapy (NAPT) to kill tumor cells by near infrared
light (NIR) [34]. Gold-EGFR conjugates have been used to
detect the cancer cells by exploiting the light scattering
properties of gold nanoconjugates [35]. This paper is
unique in that it bridges the field of nanoscience and tech-
nology with the therapy in CLL and opens up the oppor-
tunity of utilizing the technological advances of
nanoscience in the treatment of CLL.
These findings in CLL reinforce the advantages of using
gold-nanoparticle-based drug delivery system in human
malignancies. They include; increased concentration of
drug loading due to high surface area of the nanoparticles,
the ability to load multiple drugs (including the targeting
agent) on the nanoparticle and the important feature of
achieving higher local drug concentrations with reduced
systemic toxicity and enhanced efficacy. We continue to
develop this nanoparticle system in order to not only
exploit the use of gold nanoparticles as anti-angiogenic
targeted molecules but to conjugate other known chemo-
therapeutic (i.e. fludarabine) or monoclonal agents (i.e.
rituximab) to these nanoparticles as well. This delivery
system has the potential to induce cell death in CLL B cells
by not only interrupting the VEGF based survival pathway
but also by delivering effective levels of chemoimmuno-
therapeutics to the cells. In future, potential opportunities
exist to harness the size dependent optoelectronic proper-
ties of gold nanoparticles in the treatment of CLL.
Materials and methods
Patient selection and purification of lymphocytes
Blood was obtained from healthy donors or CLL patients
who had provided written informed consent. The labora-
tory study was approved by the Mayo Clinic Institutional
Review Board according to the regulations of the Declara-
tion of Helsinki. All CLL patients had a confirmed diagno-
sis using the NCI working group definition [36]. Patients
in this cohort were from all Rai stages and had not been
treated for at least 6 weeks prior to blood processing for
this study. Peripheral blood mononuclear cells (PBMC)
were separated from heparinized venous blood by density
gradient centrifugation. To remove adherent cells, PBMC
were suspended in RPMI 1640 supplemented with 10%
fetal calf serum (FCS) and incubated in plastic dishes at
37.1°C for 1 h prior to collection of non-adherent cells.
To obtain at least 95% purity of CLL B cells, non-adherent
cells were depleted of T cells by incubation with sheep
erythrocytes. In addition, we also purified CLL B cells
from magnetic bead columns. To do this, highly purified
CD19+ B cells (≥95%) were obtained from PBMC by
standard negative selection using a cocktail of subset-spe-
cific antibodies conjugated with magnetic beads (Miltenyi
Biotech, Auburn, CA, USA). These purified CLL B cells
were then either used immediately for the laboratory stud-
ies described below or cryopreserved in RPMI 1640, 20%
Immunoblot analysis of CLL B cells exposed to gold particles  (Au) alone, AbVF alone at 5 and 25 µg/ml and AU-AbVF at 5  and 25 µg/ml Figure 5
Immunoblot analysis of CLL B cells exposed to gold particles 
(Au) alone, AbVF alone at 5 and 25 µg/ml and AU-AbVF at 5 
and 25 µg/ml. Note the prominent PARP cleavage, decrease 
in caspase 3, Mcl-1 and moderate change in Bcl-2 for CLL B 
cells treated with Au-AbVF at 25 µg/ml. These changes were 
noted but less evident for Au-AbVF at the 5 µg/ml dose.Journal of Nanobiotechnology 2007, 5:4 http://www.jnanobiotechnology.com/content/5/1/4
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Internalization of Au-AbVF and Au alone by primary CLL-B cells after 1 h incubation Figure 6
Internalization of Au-AbVF and Au alone by primary CLL-B cells after 1 h incubation. 6a) nanoparticles were seen at the cell 
periphery (within uncoated tubules and vacuoles); 6b) higher magnification image of 6a; 6c and 6d) showing the internalized 
particles in different endocytic compartments. Figure 6e to 6h show the internalization of Au nanoparticles alone by primary 
CLL-B cells after 1 h incubation. 6e) Nanoparticles were seen at the cell periphery (within uncoated tubules and vacuoles); 6f) 
higher magnification image of 6e; 6f) showing the internalized particles in multivesicular bodies; and 6g) higher magnification 
image of 6f.Journal of Nanobiotechnology 2007, 5:4 http://www.jnanobiotechnology.com/content/5/1/4
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FCS, and 10% DMSO and stored in liquid nitrogen until
use.
Cell culture
Primary CLL B cells and human splenic B cells obtained
from controls were sorted by CD 19 antibody conjugated
to magnetic beads (Miltenyi Biotec, Auburn, CA, USA)
and were then cultured in serumfree AIM-V (Gibco BRL,
USA) and RPMI (Biomol, USA) supplemented with 10%
FCS, respectively. Cells were maintained at 37°C in an
atmosphere containing 95% air-5% CO2 (v/v).
Reagents
Immunological reagents that recognize the following
antigens were purchased from the indicated suppliers:
Mcl-1 from BD Pharmingen (San Diego, CA, USA); Bcl-2
from Dako Corp (Carpinteria, CA, USA); XIAP from R&D
Systems, Inc. (Minneapolis, MN, USA); β-actin from
Novus Biologicals (Littleton, CO, USA). VEGF neutraliz-
ing antibody (2C3) was a kind gift from Pergerine Phar-
maceuticals. The antibody (2C3) specifically blocks the
interaction between VEGF and VEGFR-2 [37].
Synthesis and characterization of gold nanoparticles and 
its nanoconjugates
Gold nanoparticles were synthesized according to stand-
ard wet chemical methods using sodium borohydride as a
reducing agent [11-13]. Characteristic surface plasmon
resonance (SPR) band of gold nanoparticles was observed
in the UV-Visible spectrum, confirming the presence of
spherical gold nanoparticles (Fig. 1a). TEM micrographs
showed spherical gold nanoparticles of approximately 5
nm were formed by this method (Fig. 1b). The size distri-
bution analysis of gold nanoparticles (after counting 500
individual particles) clearly shows that most of the gold
nanoparticles (~90%) are in 4–5 nm range (Fig 1c).
Binding of VEGF antibody to gold nanoparticles was done
according to our previously published report [13]. In
brief, 150 ml of gold nanoparticles were incubated with
600 µg of AbVF for 1 h at room temperature under stir-
ring. After 1 h, gold conjugates thus obtained were ultra-
centrifuged at 25000 rpm at 10°C for 1 h. The loose pellet
obtained at the bottom was collected and UV-irradiated
for 20–30 minutes before use in apoptosis assays. The
binding was monitored using UV-Visible spectroscopy.
UV-Visible spectrum was recorded on a Shimadzu model
system (UV2401 PC) and the saturation concentration
was determined.
Quantitation of AbVF in the nanoconjugates using 
thermogravimetric analysis (TGA)
For TGA analysis, 150 ml of gold nanoparticles were incu-
bated with 600 µg of AbVF for 1 h at room temperature
under stirring. After 1 h, gold conjugates were centrifuged
at 25000 rpm at 10°C for 1 h. Both the supernatant and
the loose pellet at the bottom were collected. The loose
pellet obtained after ultracentrifugation was used for the
quantification of AbVF attached on gold nanoparticles
and also for apoptosis studies with CLL B cells described
below. For TGA analysis, the pellet obtained after ultra-
centrifugation was lyophilized to obtain gold nanoconju-
gates in powder form. The lyophilized powder of
nanoconjugates was used for TGA analysis. TGA was done
using a TA Instruments Q500 thermal analyst. The TGA
data were obtained in flowing nitrogen at a heating rate of
20°C/min. Amount of drugs attached onto gold nanopar-
ticles were obtained from weight loss from the TGA curve
as previously described [10].
Studying nature of bonding by X-ray photoelectron 
spectroscopy
X-ray photoelectron spectroscopy (XPS) was performed to
find out the nature of bonding between gold nanoparti-
cles and the antibody. XPS was obtained on a PHI 5400
instrument using a Mg Kα Xray (1253.6 eV) anode source
operated at 250 W, pressure was below 2 × 10-9 torr. The
electron pass energy on the hemispherical analyzer was set
at 89.45 eV for survey scans and 17.9 eV for highresolu-
tion scans. The binding energy scale was referenced to that
of C1s (285.0 eV). Samples were prepared by drop-coat-
ing anti-VEGF165 antibody conjugated gold solution on a
clean silicon wafer and the drops were allowed to air dry
[38].
Studying apoptosis in CLL-B cells isolated from patients
To compare gold nanoconjugates containing AbVF (Au-
AbVF) to AbVF alone, a humanized anti-VEGF-A mono-
clonal antibody 2C3 (Pergerine Pharma) was co-cultured
with purified CLL B primary cells. In brief, CLL B cells (1
× 106) were co-cultured with increasing concentrations of
2C3 conjugated to gold as well as 2C3 and gold (1 µg–25
µg/ml) alone as controls for 24–72 hours. Annexin/PI
flow cytometry was done on those cells according to our
prior procedures [3]. We wish to indicate here that all the
experiments reported here were repeated in triplicate.
Immunoblotting analysis
To detect alterations of apoptotic proteins and confirm
apoptosis we used immunoblot analysis. Primary CLL B
cells were cultured in six-well tissue culture dishes and
treated with either vehicle (control) or Au alone, AbVF,
Au-AbVF for 24 h. The treated cells were then washed
three times with calcium, magnesium-free Dulbecco's
phosphate-buffered saline (PBS) and solubilized in
alkylation buffer (6 M guanidine hydrochloride, 250 mM
Tris-HCl, pH 7.4 at 21.1°C, and 10 mM EDTA supple-
mented immediately before use with 150 mM 2-mecap-
toethanol and 1 mM phenylmethylsulfonyl fluoride).
Samples were then dialyzed into 4 M urea and then 0.1%Journal of Nanobiotechnology 2007, 5:4 http://www.jnanobiotechnology.com/content/5/1/4
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SDS. Protein extracts were then separated on 5–15% SDS-
PAGE acrylamide gels and transferred to nitrocellulose
membrane and blocked with 10% Tris-saline milk (TSM).
Relevant primary antibodies were diluted in the 10% TSM
milk and incubated overnight on the shaker at room tem-
perature. After three extensive washing with 1 × PBS con-
taining 0.05% Tween 20 for 15 min, the blot was then
incubated with horseradish peroxidase-conjugated sec-
ondary antibody (KPL Inc., Gaithersburg, MD, USA)
diluted 1:8000 in 10% TSM for 1 h at room temperature.
After washing with 1× PBS containing 0.05% Tween 20 for
another 30 min, bound antibodies were detected by ECL
chemiluminescence (Amersham Pharmacia, Piscataway,
NJ, USA).
Transmission electron microscopy
TEM sample preparation involving cells, however, was
performed by treating cells with gold nanoparticles and
gold nanoconjugates for 1 h with under serum-free condi-
tions. After the incubation, CLL-B cells were centrifuged
initially at 2500 rpm for 6 min. The resultant cell pellets
were then washed thrice with PBS, and fixed in Trump's
fixative (1% glutaraldehyde and 4% formaldehyde in 0.1
M phosphate buffer, pH 7.2). Both cell types were then
rinsed for 30 min in 3 changes of 0.1 M phosphate buffer,
pH 7.2, followed by a 1 hr postfix in phosphate-buffered
1% OsO4. After rinsing in 3 changes of distilled water for
30 min, the tissue was en bloc stained with 2% uranyl ace-
tate for 30 min at 60°C. The cell was then rinsed in three
changes of distilled water, dehydrated in progressively
higher concentrations of ethanol and 100% propylene
oxide, and embedded in Spurr's resin. Thin (90 nm) sec-
tions were cut on a Reichert Ultracut E ultramicrotome,
placed on 200 mesh copper grids, and stained with lead
citrate. Micrographs were taken on a TECNAI 12 operating
at 120 KV.
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